Ascletis Pharma plans to raise HK$835 million through a share placement to advance Phase III clinical trials of its weight loss drug ASC30
February 4, 2026
Source: drugdu
39
Ascletis Pharma-B announced a proposed placement of 69.256 million shares, representing approximately 6.98% of the enlarged share capital. The placement price is HK$12.18 per share, representing a discount of approximately 4.0% to the closing price of HK$12.69 on February 2. The net proceeds are expected to be approximately HK$835 million.
The company's purpose in this round of financing is very clear: 90% of the funds (approximately HK$750 million) will be directly used for the development of its core pipeline, ASC30. ASC30 is a small-molecule oral GLP-1 receptor agonist for the treatment of obesity. This funding will be specifically used for the preparation, groundwork, and formal initiation of its global Phase III clinical trials.
https://finance.eastmoney.com/a/202602033639376910.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Obtains Drug Registration Certificate for Vitamin K1 Injection February 4, 2026
- Midea Biopharma’s SELNP platform advances oral administration of paclitaxel with dual clinical trial approvals in China and the US. February 4, 2026
- Huadong Medicine achieves another breakthrough in the autoimmune market! Roflumilast cream 0.05% has been submitted for market approval. February 4, 2026
- A win-win partnership! Jiangsu Weikaier’s Class 1 innovative drug VC005 gel has reached a cooperation agreement with Sunshine Novo. February 4, 2026
- Its groundbreaking innovative drug, Ruxolitinib Phosphate Cream, has been approved for marketing in China. It is the first and only targeted drug approved in China for the treatment of vitiligo. February 3, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
